U.S., Feb. 28 -- ClinicalTrials.gov registry received information related to the study (NCT06849167) titled 'Immunotherapy Combined with Hypofractionated Concurrent Chemoradiotherapy Followed by Immunotherapy in LA-NSCLC' on Feb. 17.
Brief Summary: Patients with locally advanced NSCLC (Non-Small Cell Lung Cancer) who have a PD-L1 TPS >= 20% will be included in this study. It aims to explore the efficacy and safety of immunotherapy combined with hypofractionated concurrent chemoradiotherapy, followed by consolidation immunotherapy.
Participants will undergo large fractionated radiotherapy with a total dose of 48Gy/16 fractions, 3Gy per fraction, 5 days a week. Participants will receive two cycles of concurrent platinum-based doublet chemot...